Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.

Experimental cell research - 15 May 2020

Zhao Kun, Lu Yanrong, Chen Younan, Cheng Jingqiu, Zhang Wengeng

Abstract excerpt

BRAF mutations occur in approximately 50% of melanoma patients. The mutated BRAF kinase continuously activates the mitogen-activated protein kinase (MAPK) pathway to promote cell growth and proliferation. Vemurafenib as a specific BRAF inhibitor can significantly prolong progression-free survival in melanoma patients. However, most patients developed resistance to Vemurafenib after 6 months. The mechanism of drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Interleukin-6

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanocytes

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Protein Isoforms

Share to STAT3 Transcription Factor

Share to Vemurafenib

Source

Identifiers

PMID: 32173467
DOI: 10.1016/j.yexcr.2020.111942

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells.PMID 32173467Read ↗

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanomaSemantic proximity Read ↗

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.Semantic proximity Read ↗

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in MelanomaSemantic proximity Read ↗

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq AnalysisSemantic proximity Read ↗

Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF InhibitorsSemantic proximity Read ↗

M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.Semantic proximity Read ↗

Demonstration of a WNT5A-IL-6 positive feedback loop in melanoma cells: Dual interference of this loop more effectively impairs melanoma cell invasion.Semantic proximity Read ↗

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in MelanomaSemantic proximity Read ↗

TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.